To clarify the survival mechanism related to the relationship between BLCA and the expression of SORL1, we explored the differences in tumour-infiltrating immune cells between patients with high and low SORL1 expression (the group allocation of patients was the same as the previous step). The gene discussed is SORL1; the disease is bladder transitional cell carcinoma.